ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2121 • 2014 ACR/ARHP Annual Meeting

    Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease

    Ghaith Mitri1, Eric Wittbrodt1, Robin Turpin1, Beni Tidwell2 and Kathy Schulman2, 1Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, 2Outcomes Research Solutions, Inc., Waltham, MA

    Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…
  • Abstract Number: 2122 • 2014 ACR/ARHP Annual Meeting

    Variation in the Prescribing Practices of Biologic Dmards

    Heather O. Tory1, Josephine A. Awosogba2, Amish J. Dave2, Jonathan S. Coblyn2, Daniel H. Solomon2 and Sonali P. Desai2, 1Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Biologic DMARDs (bDMARDs) are effective yet expensive treatments for RA. Variability in the prescribing practices of rheumatologists using these agents may be attributable to…
  • Abstract Number: 2123 • 2014 ACR/ARHP Annual Meeting

    Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis

    Chris Tonner1, Gabriela Schmajuk2 and Jinoos Yazdany2, 13333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, 2Medicine, University of California, San Francisco, San Francisco, CA

    Background/Purpose:  Biologic drugs can be obtained both through Medicare's Part B medical benefit (physician administered drugs) or Part D pharmacy benefit (self-administered drugs).  Coverage for…
  • Abstract Number: 2124 • 2014 ACR/ARHP Annual Meeting

    Characteristics of Medicare Beneficiaries Travelling Long Distances to Visit a Rheumatologist

    Gabriela Schmajuk1, Chris Tonner2 and Jinoos Yazdany3, 1Medicine / Rheumatology, UCSF / San Francisco VA, San Francisco, CA, 23333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, 3Medicine, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Studies of the distribution of rheumatologists across the United States suggest that a significant number of patients travel long distances to visit a rheumatologist. …
  • Abstract Number: 2125 • 2014 ACR/ARHP Annual Meeting

    Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study

    Louis Bessette1, Frédéric Lioté2, Carmen Moragues3, Rüdiger Moericke4, Zhang Zhiyi5, Alberto Ferreira6, Pascal Lecomte6, Sophia Kessabi6, Haijun Tian7 and Jasvinder A. Singh8,9, 1CHUL, Quebec, QC, Canada, 2Hôpital Lariboisière & University Paris Diderot, Paris, France, 3Hospital Platón, Barcelona, Italy, 4Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, 5The First Affiliated Hospital of Haerbin Medical University, Haerbin, China, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Mayo Clinic, Rochester, MN, 9University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Refractory gouty arthritis (RGA) is a condition characterized by appearance of recurrent flares and contraindication, intolerance, or lack of efficacy to first-line anti-inflammatory therapy…
  • Abstract Number: 2126 • 2014 ACR/ARHP Annual Meeting

    The Utility of Digital Activity Fluorescence Optical Imaging in Quantifying Hand and Wrist Inflammation in Rheumatic Diseases

    Yogan Kisten1, Noémi Györi1, Hamed Rezaei2,3, Adrian Levitsky4, Anna Karlsson1, Erik af Klint3 and Ronald van Vollenhoven3,5, 1Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, 2Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 3Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The rheumatology clinic of the Karolinska University Hospital, Stockholm, Sweden, 4The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, 5Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden

    Background/Purpose The objective detection and quantification of disease activity in its earliest pathophysiological stage is critical for achieving optimal therapy results. Fluorescence optical imaging (FOI)…
  • Abstract Number: 2127 • 2014 ACR/ARHP Annual Meeting

    Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission

    Y.Y.J. Gent1, M.M. ter Wee1, D den Uyl1, N. Ahmadi2, W.F. Lems3, O.S. Hoekstra4, A.E. Voskuyl1 and C.J. Van der Laken3, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Radiology, VU University Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU Medical Center, Amsterdam, Netherlands, 4Nuclear Medicine, VU Medical Center, Amsterdam, Netherlands

    Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical…
  • Abstract Number: 2128 • 2014 ACR/ARHP Annual Meeting

    Effectiveness of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia-like Illness

    Hideyuki Horikoshi1, Takashi Nakanishi1, Reiko Takahashi1, Fumihiko Kimura2 and Kenji Itoh1, 1Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, 2National Defense Medical College, Tokorozawa, Japan

    Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that affects the elderly.  It is characterized by pain and stiffness in the shoulder and pelvic girdles. …
  • Abstract Number: 2129 • 2014 ACR/ARHP Annual Meeting

    Sensitivity and Specificity of the “Green Nail” Sign in Fluorescence Optical Imaging in Psoriatic Arthritis

    Oliver Wiemann1, Stephanie G. Werner1, Hannah Röver1, Gudrun Lind-Albrecht1, Sabine Mettler1, Marina Backhaus2 and Hans-Eckhard Langer1, 1RHIO (Rheumatology, Immunology, Osteology), Duesseldorf, Germany, 2Rheumatology/Immunology, Charite University Hospital, Berlin, Germany

    Background/Purpose ICG-enhanced fluorescence optical imaging (FOI) is a novel technology for the assessment of inflammation in arthritis [1,2]. Recent work suggested that a “green nail”…
  • Abstract Number: 2105 • 2014 ACR/ARHP Annual Meeting

    Nonsurgical Treatment Patterns in Patients with Chronic Spinal Cord Injury

    Brian Le1, Monique Bethel2, Lauren Bailey3, Frances Weaver3, Stephen Burns4, Jelena Svircev4, Michael Heggeness5 and Laura Carbone6, 1Medicine, Georgia Regents University, Augusta, GA, 2Internal Medicine, Georgia Regents University, Augusta, GA, 3Edward Hines Jr. VA Hospital, Chicago, IL, 4VA Puget Sound Healthcare System, Seattle, WA, 5Orthopaedic Surgery, University of Kansas School of Medicine, Kansas City, KS, 6Medicine, Charlie Norwood VA Medical Center, Augusta, GA

    Background/Purpose: Sublesional loss of bone mineral density is a common complication in patients with chronic spinal cord injury (SCI) putting them at high risk for…
  • Abstract Number: 2104 • 2014 ACR/ARHP Annual Meeting

    Effectiveness of a Workplace Integrated Care Intervention on Work Productivity in Workers with Rheumatoid Arthritis

    Myrthe van Vilsteren1,2, Cécile Boot1,2, Dirkjan van Schaardenburg3, Romy Steenbeek2,4, A.E. Voskuyl5 and Johannes Anema1,2,6, 1Department of Public and Occupational Health, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, 2Body@Work, Research Center Physical Activity, Work and Health, TNO-VU University Medical Center, Amsterdam, Netherlands, 3Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, 4TNO Work and Health, Hoofddorp, Netherlands, 5Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 6Research Center for Insurance Medicine AMC-UMCG-UWV-VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease with a profound impact on a person’s working life. Besides permanent work disability and sick leave,…
  • Abstract Number: 2103 • 2014 ACR/ARHP Annual Meeting

    Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting

    E Alemao1, S Joo2, H Kawabata1, S Banerjee1, M Frits3, C Iannaccone3, N Shadick3 and M Weinblatt3, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Hopewell, NJ, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Guidelines in RA recommend that treatment should be aimed at reaching a target of remission or low disease activity (LDA) as soon as possible,…
  • Abstract Number: 2102 • 2014 ACR/ARHP Annual Meeting

    A Tissue-Specific Lincrna in the TRAF1-C5 Risk Locus As a Putative Cis-Regulator, Bridging Genetics and Disease

    Tobias Messemaker1, Rute Marques1, Tom Huizinga1, Alwin Adriaans1, Aleida Bakker1, Arend Berendsen1, Nina Daha2, R E M Toes1, Harald Mikkers3 and Fina Kurreeman1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose In the last decade genome wide association studies (GWAS) have identified genetic polymorphisms that associate with Rheumatoid arthritis (RA). However, the way these genetic…
  • Abstract Number: 2101 • 2014 ACR/ARHP Annual Meeting

    Epigenetic Study of Advanced Ankylosis in Patients with Ankylosing Spondylitis

    Darren O'Reilly1, Yuhua Zhang2, Nayef Al Ghanim3, Rose Ardern3, Alexandra Munn3, Sean Hamilton3, Guangju Zhai2 and Proton Rahman3, 1Memorial University of Newfoundland, St. John's, NF, Canada, 2Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada

    Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory spinal disease characterized by ankylosis of the spine. A subset of patients develops significant ankylosis resulting in mobility…
  • Abstract Number: 2100 • 2014 ACR/ARHP Annual Meeting

    Activation of NFkβ Pathways in Sjögren’s Syndrome Related Lymphomagenesis-Role of the His159Tyr Mutation of the BAFF-R Receptor

    Clio Mavragani1, Adrianos Nezos2, Aristea Papageorgiou3, Haralampos M. Moutsopoulos3, Athanasios G. Tzioufas4 and Michael Voulgarelis3, 1Department of Physiology, School of Medicine, University of Athens, Athens, Greece, 2Department of Physiology, School of Medicine, University of Athens, Athens, Greece, 3Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, 4Pathophysiology, School of Medicine, National University of Athens, Athens, Greece

    Background/Purpose: Sjögren’s Syndrome (SS) bears the highest risk for lymphoma development among all autoimmune diseases. A growing body of evidence suggests activation of NFκB pathways…
  • « Previous Page
  • 1
  • …
  • 2091
  • 2092
  • 2093
  • 2094
  • 2095
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology